Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics, DPC Lebanon Ink Pact to Distribute Colorectal Cancer MDx in Middle East

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics today announced an exclusive agreement with DPC Lebanon for the distribution of the Epi proColon colorectal cancer test in parts of the Middle East.

Under the agreement, DPC Lebanon will distribute the test for the early detection of colorectal cancer in blood in Lebanon, the United Arab Emirates, Saudi Arabia, Qatar, Kuwait, Syria, Jordan, and Egypt.

Financial terms were not disclosed.

Epigenomics last month inked a deal for distribution of the test in Israel with Pronto and in Turkey with Dateks. Today's deal "completes the picture for the Middle East," Geert Nygaard, CEO of Epigenomics, said in a statement. "DPC will join Dateks and Pronto as important partners in our continuously growing distributor network for our Epi proColon product."

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.